Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...

The European drugs regulator said on Friday it was reviewing anti hair-loss drugs, including Organon's Propecia and its ...

The European health regulator said on Friday it has started a review of anti hair-loss drugs, including Merck's Propecia, ...

Vice President Kamala Harris allies in the business community are trying to give her a boost over Donald Trump.

Anyone crafting a bull case for the pharmaceutical giant Merck (NYSE: MRK) should include Keytruda as the company's best ...

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to ...

Shares of Merck & Co. Inc. MRK slipped 0.37% to $109.77 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.90% to 5,751.07 and ...

The European drugs regulator said on Friday it was reviewing anti hair-loss drugs, including Organon's Propecia, for the ...

Summit Therapeutics (NASDAQ: SMMT). This California-based biotech is developing a cancer medicine that has produced excellent clinical trial results in one area where Keytruda is the leader. Summit ...

BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $144.12, ...

Merck (MRK) is one of the worst-performing stocks in the Dow Jones Industrial Average (DJIA) on Thursday. The US government ...